ES2103834T3 - Complementacion de receptores de la superficie celular. - Google Patents
Complementacion de receptores de la superficie celular.Info
- Publication number
- ES2103834T3 ES2103834T3 ES92100186T ES92100186T ES2103834T3 ES 2103834 T3 ES2103834 T3 ES 2103834T3 ES 92100186 T ES92100186 T ES 92100186T ES 92100186 T ES92100186 T ES 92100186T ES 2103834 T3 ES2103834 T3 ES 2103834T3
- Authority
- ES
- Spain
- Prior art keywords
- substance
- receptors
- cells
- binding
- monocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Dental Preparations (AREA)
- Cereal-Derived Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
UN METODO DE CONTROLAR LA CANTIDAD DE SUSTANCIA BIOLOGICAMENTE ACTIVA UNIDA A UNA SUPERFICIE CELULAR TENIENDO AMBOS RECEPTORES, A LA SUSTANCIA Y RECEPTORES PARA EL DOMINIO FC DE UN ANTICUERPO QUE PUEDE FORMAR UN COMPLEJO CON LA SUSTANCIA U OTROS ANTICUERPOS QUE PUEDEN FORMAR COMPLEJO CON LA SUSTANCIA. MEDIANTE LA EXPLOTACION DE LAS GENERALMENTE MAS NUMEROSAS POSICIONES RECEPTORAS FC, LA SUSTANCIA UNIDA PUEDE SER AUMENTADA Y/O CONTROLADA. EL METODO CONTEMPLA EL CONTROL DE CANTIDADES DE SUSTANCIAS TALES COMO CITOQUINAS, HORMONAS Y FACTORES DE CRECIMIENTO QUE ESTAN ASOCIADOS CON CELULAS TALES COMO MONOCITOS, MACROFAGOS, GRANULOCITOS, CELULAS B, CELULAS T Y PLAQUETAS. SE ILUSTRA EL METODO UTILIZANDO ANTICUERPOS CONJUGADOS A FACTOR DE NECROSIS TISULAR (TNF) PARA AUMENTAR LA UNION DE TNF A MONOCITOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64121191A | 1991-01-15 | 1991-01-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2103834T3 true ES2103834T3 (es) | 1997-10-01 |
Family
ID=24571410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES92100186T Expired - Lifetime ES2103834T3 (es) | 1991-01-15 | 1992-01-08 | Complementacion de receptores de la superficie celular. |
Country Status (8)
Country | Link |
---|---|
US (1) | US5658746A (es) |
EP (1) | EP0495376B1 (es) |
JP (1) | JP3199811B2 (es) |
AT (1) | ATE153768T1 (es) |
CA (1) | CA2059060C (es) |
DE (1) | DE69219913T2 (es) |
ES (1) | ES2103834T3 (es) |
GR (1) | GR3024501T3 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO280796A0 (en) * | 1996-10-07 | 1996-10-31 | Austin Research Institute, The | Methods of activating or enhancing FC receptors |
MXPA03007878A (es) * | 2001-03-02 | 2004-07-08 | Medimmune Inc | Metodos de prevencion o tratamiento de alteraciones inflamatorias o autoinmunes mediante la administracion de los antagonistas alfav, beta3 de integrina. |
CA2481747A1 (en) | 2002-04-12 | 2003-10-23 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
KR20120035234A (ko) | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
US7351739B2 (en) * | 2004-04-30 | 2008-04-01 | Wellgen, Inc. | Bioactive compounds and methods of uses thereof |
CA2585717A1 (en) | 2004-10-27 | 2006-05-04 | Medimmune Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
AU2007272970C1 (en) | 2006-07-11 | 2013-01-10 | Roy C. Levitt | Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors |
AU2007284690A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
RU2549701C2 (ru) | 2007-05-07 | 2015-04-27 | Медиммун, Ллк | Анти-icos антитела и их применение в лечении онкологических, связанных с трансплантацией и аутоиммунных заболеваний |
BRPI0921845A2 (pt) | 2008-11-12 | 2019-09-17 | Medimmune Llc | formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3882225A (en) * | 1968-12-09 | 1975-05-06 | Miles Lab | Direct agglutination immunological reagent |
CA1208546A (en) * | 1981-09-08 | 1986-07-29 | Anthony Cerami | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
US4551435A (en) * | 1983-08-24 | 1985-11-05 | Immunicon, Inc. | Selective removal of immunospecifically recognizable substances from solution |
US4770995A (en) * | 1985-08-29 | 1988-09-13 | New York Blood Center, Inc | Detection of the sensitivity of cells to the effects of tumor necrosis factor and lymphotoxin |
US5063151A (en) * | 1985-09-20 | 1991-11-05 | Biometallics, Inc. | Immunoassay method and kit |
US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4954617A (en) * | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
AU3284289A (en) * | 1987-12-04 | 1989-07-05 | Schering Biotech Corporation | Human fc-gamma receptor |
US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
KR0162259B1 (ko) * | 1989-12-05 | 1998-12-01 | 아미 펙터 | 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체 |
-
1992
- 1992-01-08 AT AT92100186T patent/ATE153768T1/de not_active IP Right Cessation
- 1992-01-08 ES ES92100186T patent/ES2103834T3/es not_active Expired - Lifetime
- 1992-01-08 DE DE69219913T patent/DE69219913T2/de not_active Expired - Lifetime
- 1992-01-08 EP EP92100186A patent/EP0495376B1/en not_active Expired - Lifetime
- 1992-01-09 CA CA002059060A patent/CA2059060C/en not_active Expired - Lifetime
- 1992-01-10 JP JP02067492A patent/JP3199811B2/ja not_active Expired - Lifetime
-
1995
- 1995-11-03 US US08/552,432 patent/US5658746A/en not_active Expired - Lifetime
-
1997
- 1997-08-21 GR GR970402140T patent/GR3024501T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP3199811B2 (ja) | 2001-08-20 |
ATE153768T1 (de) | 1997-06-15 |
US5658746A (en) | 1997-08-19 |
GR3024501T3 (en) | 1997-11-28 |
DE69219913T2 (de) | 1997-09-11 |
EP0495376A3 (en) | 1993-04-28 |
EP0495376B1 (en) | 1997-05-28 |
CA2059060C (en) | 2002-07-23 |
JPH05215752A (ja) | 1993-08-24 |
EP0495376A2 (en) | 1992-07-22 |
CA2059060A1 (en) | 1992-07-16 |
DE69219913D1 (de) | 1997-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2103834T3 (es) | Complementacion de receptores de la superficie celular. | |
AU4128089A (en) | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same | |
ATE195254T1 (de) | Fusionsproteine mit gemischter spezifität | |
AU648617B2 (en) | Monoclonal antibodies against human tumor necrosis factor alpha | |
DE69333950D1 (de) | Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden | |
EP2016953A3 (en) | Vascular endothelial cell growth factor antagonists and uses thereof | |
ES2093623T3 (es) | Receptores monovalentes y oligovalentes, bioespecificos y oligoespecificos, su preparacion y empleo. | |
AU1774692A (en) | Absorbent mat, especially for organic hydrocarbons | |
ATE47155T1 (de) | Monoklonaler antikoerper. | |
BR9007643A (pt) | Metodo para se conseguir a epitelizacao de lentes sinteticas | |
HU9202073D0 (en) | Antibody-antagonists of human interleucin-4 | |
ATE177475T1 (de) | Monoklonale antikörper gegen c-kit | |
EP0193154A3 (en) | Potential-causing element for immunosensor | |
EP1932856A3 (en) | IL-8 inhibitors | |
EP0246638A3 (en) | Biologically modified synthetic grafts | |
Helseth et al. | Effects of type beta transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors | |
AU3063297A (en) | Cellular internalization of pigr stalk and associated ligands | |
ATE71149T1 (de) | Monoklonale antikoerper. | |
JPS6468661A (en) | Immunological method for determining isolated substance having hapten nature | |
ES2061566T3 (es) | Anticuerpos monoclonales contra la proteina e7 del papilomavirus humano tipo 16, procedimiento para su preparacion, asi como su empleo. | |
EP1172386A4 (en) | FUNCTIONALIZED POLYMER OF GLYCOSAMINOGLYCAN, MEDICINAL PRODUCTS AND MEDICAL INSTRUMENTS FOR THEIR PRODUCTION | |
NO902603L (no) | Regulering av karakteristiske biologiske egenskaper i et materiale. | |
ATE70311T1 (de) | Monoklonale antikoerper gegen menschliche igerezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper. | |
DK521385A (da) | Fremgangsmaade til fremstilling af betonmasse og ifoelge fremgangsmaaden fremstillet betonmasse | |
Benjamin et al. | Differential effects of teleocidin on TNFα receptor regulation in human B cell lines: Relationship to coexpression of IL-2 and IL-1 receptors and to lymphokine secretion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 495376 Country of ref document: ES |